Clinical Trials Browser

Phase 2 × Active not recruiting × Nasopharyngeal Carcinoma × Clear all

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT04825990 2026-06-01

POINT

Phase 2 Active not recruiting

30 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03930498 2026-05-11

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

68 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

150 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

41 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT05126719 2026-02-06